Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial

Can-Fite has reported that its Phase IIa study of Namodenoson in advanced pancreatic ductal adenocarcinoma patients achieved its primary safety endpoint. Namodenoson showed a tolerable safety profile consistent with previous studies. The findings highlight a subgroup of heavily pretreated pancreatic cancer patients achieving extended survival with Namodenoson therapy. Credit: Jo Panuwat D/Shutterstock.com. Can-Fite has reported that its Phase IIa study of Namodenoson in advanced pancreatic ductal adenocarcinoma patients achieved its primary safety endpoint. The open-label study also showed durable overall survival outcomes. LOA and PTSR Model Fesomersen Sodium in End-Stage Kidney Disease ... Reports LOA and PTSR Model -…

Source: Clinical Trials Arena